Agonists of GLP-1 receptors (GLP-1 RAs) such as liraglutide, dulaglutide and semaglutide have been shown to achieve substantial glycaemic control and facilitate weight reduction, and have been used for the management of T2D and obesity with excellent results [11,12]. The gene discussed is GLP1R; the disease is Obesity.